PDF Cover

Insulin Pens Market

The market for Insulin Pens was estimated at $8.7 billion in 2025; it is anticipated to increase to $12.9 billion by 2030, with projections indicating growth to around $19.3 billion by 2035.

Report ID:DS1801022
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Insulin Pens
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Insulin Pens Market Outlook

Revenue, 2025

$8.7B

Forecast, 2035

$19.3B

CAGR, 2026 - 2035

8.3%

The Insulin Pens industry revenue is expected to be around $8.7 billion in 2026 and expected to showcase growth with 8.3% CAGR between 2026 and 2035. The insulin pens market is a crucial component of diabetes treatment today due to the rapid rise in diabetes cases and the widespread adoption of patient centric insulin devices. As a result, there is considerable focus on improving diabetic control. Because of improved precision in dosing, convenience for the patient and a lower risk of dosing mistakes, insulin pens are increasingly preferred by payers and healthcare providers over the traditional insulin vial and syringe. Innovations to insulin pens, combined with their connectivity to digital systems which diabetes patients use to manage their condition, as well as insulin becoming more widely available in developing nations, have all served to underline the continued importance of insulin pens. They are used by people who have both 1 and 2 diabetes. The increasing demand for insulin pens is supported by positive reimbursement policies, endorsements from medical guidelines and the trend of simplifying the administration of basal bolus therapy in outpatient clinics. This has reinforced the insulin pen as a strategic market within diabetes care products.

Advanced insulin delivery systems in pen form are designed to make insulin dosing easier and more precise through prefilled or cartridge use, using thin needles and a turn dial to select the dose along with ergonomic design which also increases safety. Their main features include accurate dose adjustment, the option of being taken on the move, discreet use and increasingly digital dose records that can be stored and which enable real time tracking of insulin treatment. Insulin pens are used primarily in the treatment of 2 diabetes and 1 diabetes. These two conditions account for a significant 86.1% of insulin pen use, demonstrating the preference of medical professionals for insulin pens in the treatment of patients with these conditions over others of insulin. The disposable insulin pens sector led the way in sales at $4.89 billion in 2025. This growth is attributed to the reduced risk of contamination and the convenience they offer. The pens are also ideal for long term therapy which requires a large volume of insulin. Smart and reusable pens are however gaining popularity, mainly among those who are tech aware and cost conscious. The trend towards a greater patient involvement with their glucose tracking is driven by insulin delivery devices that are able to integrate with smartphone apps. Additionally manufacturers are developing solutions to improve adherence by diabetic patients. Insulin pens for children and the elderly are designed with their particular needs in mind. Furthermore, there is a growing trend towards more eco friendly and sustainable insulin pen design.

Insulin Pens market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Insulin Pens Market Outlook

Market Key Insights

  • The Insulin Pens market is projected to grow from $8.7 billion in 2025 to $19.3 billion in 2035. This represents a CAGR of 8.3%, reflecting rising demand across Diabetes Management and Home Healthcare.

  • This market is dominated by well known businesses such as Medtronic, Novo Nordisk A/S and Sanofi.

  • The United States and Germany together are the largest market in the insulin pens market. They are forecast to grow at a CAGR ranging from 6.1% to 8.7% during the period 2025 to 2030.

  • The highest growth rate is expected to be in emerging markets such as India, Brazil and France, at a compound annual growth rate of between 8% and 10.4%.

  • The shift to smart insulin pens will drive the insulin pens market to grow by $1 billion by 2030.

  • The insulin pens sector will expand by $10.6 billion between 2025 and 2035 with manufacturers aiming at capturing a bigger share in the 2 diabetes application market.

  • The insulin pen market is expected to see a 122% expansion between 2035 and 2025 due to the growing incidence of diabetes and the improvements in insulin delivery technology.

insulin pens market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Insulin Pens - Country Share Analysis

Opportunities in the Insulin Pens

There has been a rapid increase in the incidence of 2 diabetes in older people in the emerging Asian countries. Insulin pens are also used by relatively few patients especially in rural locations. This group can be effectively targeted by the manufacturers through the development of straightforward disposable insulin pens which are prefilled and require minimal training for self administration. Public hospitals pharmacies and community healthcare workers may join forces to make these diabetes management systems available in home healthcare packages. In this region, the sharps pens which are used to dispense insulin should see the greatest increase in volume, driven by factors including convenience, lower price point and reduced maintenance requirements.

Growth Opportunities in North America and Asia-Pacific

In North America insulin pens are driven primarily by two diabetes therapy, payers and medical staff here choosing the convenient insulin delivery device in order to improve the level of compliance with treatment in the general ageing population who have other health problems. Key region's of focus are the smart insulin pens designed for high end use which integrate seamlessly with digital diabetes management systems and telemedicine. Additionally, emphasis should be placed on reusable insulin pens. These pens feature dose counters and are linked to health systems eco friendly purchasing methods. In the diabetes care devices market, competition is becoming ever fiercer for brands of injectable devices. However, it is increasingly influenced by formulary access as well as pharmacy benefit managers. Additionally, there are lower priced alternatives entering the market. These are making price pressures, forcing manufacturers to concentrate on developing new features for their products. These features include dose memory capabilities, ergonomically designed pen needles and connectivity. In the region the factors which drive the demand include high incidence of obesity, guidelines which recommend early treatment with insulin for 2 diabetes sufferers, there is full health insurance to cover the cost of more advanced insulin pens and a preference among patients for using insulin pens which are small, pre filled and give less anxiety when being injected, thus helping to control the diabetes better.
In the Asia Pacific region insulin pens are mainly used by people with 2 diabetes; this is due to a rapidly increasing prevalence of the condition in urban populations and the underutilisation of modern insulin delivery systems when compared to syringes and vials. In fact, the greatest opportunities appear to be in cost optimised, prefilled insulin pens for mass markets, plus manufacturing that is localised to meet the needs of price sensitive markets, and partnerships that distribute on a large scale to secondary cities where diabetes care infrastructure is developing. The market for reusable insulin pens and the corresponding needles is a competitive field. It is comprised of major global companies as well as several regional manufacturers which specialise in low cost products. Regional companies are succeeding by focusing on the value they offer and by working closely with local distribution networks. The key drivers of growth in this region are an increase in screening for diabetes, greater reimbursement for vital diabetes care equipment, government efforts to improve the treatment of women suffering from gestational diabetes and growing acceptance of insulin pens as a safer and more convenient long term option for diabetic patients.

Market Dynamics and Supply Chain

01

Driver: Rising diabetes prevalence combined with smart delivery innovation accelerating patient-centric insulin management

The insulin pens market is also driven by the parallel rise in global diabetes incidence and rapid innovation in insulin delivery technologies. Increasing diagnosis of type 1 and insulin-dependent type 2 diabetes is also expanding the long-term user base, particularly among aging populations and younger urban cohorts with lifestyle-related risk factors. In parallel, manufacturers are also integrating smart features such as dose memory, Bluetooth connectivity, and app-based tracking into reusable insulin pens. These advancements improve dosing accuracy, reduce missed injections, and support personalized therapy optimization. Niche adoption is also growing among digitally engaged patients and clinicians seeking data-driven glycemic control. Together, epidemiological pressure and connected-device innovation are also reshaping insulin pens from simple delivery tools into intelligent disease management devices.
Healthcare systems are also increasingly promoting home-based chronic disease management to reduce hospital burden and long-term costs. Insulin pens, with minimal training requirements and portability, align well with this shift. also advances in ergonomic design, finer needles, and simplified dose selection have also improved usability for elderly and visually impaired patients. This transition supports higher adherence rates outside clinical settings and encourages broader physician prescribing, particularly for newly insulin-initiated patients.
02

Restraint: Persistent affordability challenges and reimbursement gaps limiting insulin pen penetration in price-sensitive markets

High costs of branded insulin pens and limited reimbursement coverage remain major barriers, especially in emerging economies. Patients often shift to cheaper vial-and-syringe alternatives, directly reducing insulin pen sales volumes. Inconsistent insurance coverage also discourages long-term adoption, impacting recurring revenue streams and slowing market expansion despite clinical advantages.
03

Opportunity: Expanding use of affordable disposable Insulin Pens in public primary healthcare across Latin America and Adoption of smart connected Insulin Pens by urban diabetes patients in North America and Europe

While there is an emphasis in the countries of Latin America on cost effective diabetes control through public primary healthcare, insulin pens continue to be seen as high end tools. The production costs of insulin pens could be reduced by manufacturers through government tenders and partnerships with local filling companies. Furthermore, they could establish a pilot programme which ties reimbursement to the clinical outcomes achieved by the insulin pens. Campaigns targeting both patients and nurses by way of education will help to reduce the misuse of vials and syringes and hypoglycaemia as a result of incorrect dosages. The disposable insulin pen is expected to show the quickest sales growth in this market. This is because of a large number of healthcare providers covering the cost of the pens and population wide screening programmes.
Increasingly, North American and European urban diabetics who are familiar with technology are expecting that insulin pens will be intelligent. They should be able to synchronise insulin dosage with both blood glucose monitors and smartphone apps. By incorporating insulin pens into digital health platforms, individuals can have data on their insulin dosage monitored, insulin levels tracked and health professionals can remotely monitor their condition. The global disposable pen market is predicted to grow from 4.89 billion US dollars in 2025 to 6.96 billion by 2030. In the same period, the use of reusable insulin pens is expected to rise at a compound annual growth rate of 9.54% from 3.8 billion US dollars to nearly 6 billion US dollars.
04

Challenge: Regulatory scrutiny and device compatibility constraints complicating product launches and lifecycle upgrades

Stringent regulatory approval processes for combination drug-device products delay market entry of advanced insulin pens. Additionally, compatibility issues between pens and specific insulin cartridges restrict interchangeability. These challenges increase development costs, limit rapid innovation cycles, and constrain manufacturers’ ability to scale new offerings across multiple regions.

Supply Chain Landscape

1

Insulin API Production

Novo Nordisk A/SEli Lilly and CompanySanofi
2

Insulin Pens Components

Ypsomed AGSHL MedicalOwen Mumford
3

Disposable Insulin Pens

Novo Nordisk A/SSanofiEli Lilly and Company
4

Diabetes Patient Use

type 1 diabetes patientstype 2 diabetes patientshospitals & clinics
Insulin Pens - Supply Chain

Use Cases of Insulin Pens in Diabetes Management & Home Healthcare

Diabetes Management : Insulin pens are commonly utilized in the treatment of diabetes. Whether its Type 1 or Type 2 diabetes; they offer an precise method for administering various insulin types into the body compared to the traditional syringe vials approach. One key advantage of these pens is their portability feature that enables users to carry and use them wherever needed. Major players in the industry such, as Novo Nordisk and Sanofi are recognized for manufacturing high quality insulin pens specifically designed for this purpose.
Home Healthcare : Insulin pens have brought about a change in healthcare at home by making diabetes management easier without the need for frequent visits to the hospital They are easy to use and dont require as much skill as insulin syringes do Additionally they come with a memory feature that stores past dosages helping patients follow their insulin treatment better Some well known companies, in this field are Eli Lilly and Company and BD

Recent Developments

In recent insulin pens market developments, manufacturers are heavily investing in smart connected delivery technology with Bluetooth-enabled pens and CGM integration gaining regulatory clearances and commercial launches, improving dose tracking and real-time data sharing with healthcare providers. Novo Nordisk, Medtronic and Sanofi have expanded digital offerings and regional launches, while pricing initiatives like California’s affordable state-branded pens aim to broaden accessibility and address cost barriers. A key trend is the integration of digital health ecosystems into insulin therapy, enhancing adherence and personalized diabetes management.

January 2025 : Novo Nordisk A/S launched Awiqli (insulin icodec Injection) in Japan in a prefilled FlexTouch insulin pen, expanding its diabetes treatment portfolio and geographic reach in the Asia-Pacific region.
December 2024 : Medtronic received US FDA approval for the InPen System a home-use reusable smart insulin pen for self-injection in patients aged 7 and older, expanding its connected diabetes device offerings.
July 2023 : Ypsomed AG partnered with Civica, Inc. for the production and supply of insulin dosing injector pens to support Civica’s lower-cost insulin offerings (glargine, lispro, aspart) with pen formats to enhance affordability in the U.S. market.

Impact of Industry Transitions on the Insulin Pens Market

As a core segment of the Medical Device industry, the Insulin Pens market develops in line with broader industry shifts. Over recent years, transitions such as Shift towards Smart Insulin Pens and Disposable to Sustainable Design have redefined priorities across the Medical Device sector, influencing how the Insulin Pens market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift towards Smart Insulin Pens

The global insulin pens market is being transformed by the Smart Insulin Pens, from a traditional method of administering drugs to a modern data driven tool for diabetes care. Market analysts anticipate a rise of an additional billion dollars by the year 2030. The integration of smart insulin pens, precise dose tracking and real time connectivity along with mobile health monitoring technologies improves patient adherence and enables healthcare practitioners to make informed decisions. The integration of technology into patient health care helps improve care for those with chronic diseases by reducing the inconsistency of blood sugar levels and eliminating medication errors. Healthcare providers are now focusing their diabetes treatments on the outcomes. In particular, new smart insulin pens are providing a strategic competitive advantage with the next generation of diabetes treatments, in turn they alter the value proposition that long term insulin delivery has.
02

Disposable to Sustainable Design

Another major transition is the gradual shift from disposable insulin pens toward reusable and environmentally conscious designs. Growing regulatory and consumer focus on medical waste reduction is pushing manufacturers to develop refillable pens with longer lifespans. This impacts plastics suppliers, cartridge manufacturers, and recycling service providers within the healthcare supply chain. Reusable pens also enable integration of higher-end features, supporting premium pricing strategies. While disposables still dominate volumes, sustainability-driven innovation is redefining product portfolios and influencing procurement decisions by hospitals and payers globally.